To date, no data has been reported for BTK inhibitors currently in autoimmune disease clinical trials regarding the effects of BTK cysteine 481 mutations on drug efficacy or whether such mutations are common in the autoimmune diseases studied with these drugs. Here, BTK is linked to autoimmune disease.